Natixis Advisors LLC Increases Stake in Solventum Co. (NYSE:SOLV)

Natixis Advisors LLC raised its holdings in shares of Solventum Co. (NYSE:SOLV) by 271.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,616 shares of the company’s stock after buying an additional 34,797 shares during the quarter. Natixis Advisors LLC’s holdings in Solventum were worth $3,320,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. LRI Investments LLC purchased a new stake in Solventum in the 1st quarter valued at $43,000. Price T Rowe Associates Inc. MD purchased a new position in Solventum in the first quarter worth approximately $5,889,000. EverSource Wealth Advisors LLC purchased a new stake in Solventum in the first quarter valued at $30,000. GAMMA Investing LLC acquired a new position in shares of Solventum in the 2nd quarter valued at $74,000. Finally, Massmutual Trust Co. FSB ADV purchased a new position in shares of Solventum during the 2nd quarter worth $34,000.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on SOLV shares. Stifel Nicolaus began coverage on shares of Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price objective on the stock. BTIG Research initiated coverage on shares of Solventum in a research note on Thursday, September 5th. They issued a “neutral” rating on the stock. Piper Sandler increased their price objective on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Wells Fargo & Company cut their price target on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research note on Friday, August 9th. Finally, Morgan Stanley increased their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $68.00.

Solventum Price Performance

Shares of NYSE:SOLV opened at $70.81 on Friday. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05. The company’s 50 day moving average is $70.53 and its two-hundred day moving average is $62.33. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.